Last week’s MM&M webcast titled “From Selling Pills to Selling Health Outcomes” was packed with thought provoking material. Joining the podcast were Daniel Hawkins (Clarion Healthcare Consulting), Dennis Urbaniak (Sanofi-Aventis) and Dan Rubin (inVentiv Patient …
Read the full story »
The Wall Street Journal reported in June that according to Federal Trade Commission Chairman, Jon Leibowitz, originator pharma companies were costing consumers $3.5 billion annually through making contracts with generic companies that delay the market entry of generic versions of their drugs.
The way these contracts work is that pharma companies will pay a lump-sum of money to the generic manufacturers for their agreement to not challenge the patents surrounding a particular blockbuster product. In many cases a single generic company walks away from such deals with a huge pay-out and security in knowing they will eventually anyway be the first generic to market, granting them 6 month market exclusivity over other generic entrants.
The practice is described by Mr. Leibowitz as having “opened a Pandora’s box of settlements with generic firms competing to be the first to get paid-off to stay out of the market instead of competing to be the first to come to market”.
We can only agree with his assessment, these delay-contracts run counter to the spirit of the generics industry and should not be used by generic companies of high ethical standards.
The Wall Street Journal reported in June that according to Federal Trade Commission Chairman, Jon Leibowitz, originator pharma companies were costing consumers $3.5 billion annually through making contracts with generic companies that delay the market …
This slide by presented by Daniel Hawkins in the MM&M podcast clearly shows why there will soon no longer be a distinction between originator pharma and generic companies. Not many words needed.
Last week’s MM&M webcast titled “From Selling Pills to Selling Health Outcomes” was packed with thought provoking material. Joining the podcast were Daniel Hawkins (Clarion Healthcare Consulting), Dennis Urbaniak (Sanofi-Aventis) and Dan Rubin (inVentiv Patient …
Guest post by BullPharma (Portugal) :
The world is changing, and more and more challenges are in front of the Pharmaceutical Industry. In our day-to-day business vocabulary some words are mandatory – globalization, crisis, cost …
You can’t imagine our surprise today when we saw that Pfizer has announced that it will license injectable and solid dosage forms from Aurobindo. We wrote about Pfizer’s new generics strategy on monday, but we …
“If you can’t beat them, join them”. So goes the old saying that is proving more true day-by-day in the pharma industry. A few years ago it would have been unthinkable that Pfizer, the world’s …
![Big pharma grows a [heart] ?](http://www.alensagenerics.com/wp-content/themes/arthemia-premium/scripts/timthumb.php?src=http://www.alensagenerics.com/wp-content/uploads/2009/02/heart-in-hands-300x295.jpg&w=80&h=80&zc=1&q=100)
Two very positive announcements were made last week by Andrew Witty, chief executive of Galxo SmithKline. The first covers the price of medicines in developing nations which he said Glaxo would cap at no more …
Even as patents on huge blockbuster drugs are still expiring, the smart generics companies have been preparing for some time for a future in which there are fewer and fewer syntehsized molecules to copy and …
Following the death of Mr. Merckle, the sale of his empire continues at a swift pace. The Independent is reporting that Phoenix UK, with a turnover of €1.2bn and controlling 15 per cent of the …
The first generics casualty of the financial crisis was Ratiopharm which is now being sold my the Merckle family to make up for their recent stock market losses. Now Actavis, the fifth largest generics company …
Although we’ve seen a huge increase in the number of clients going straight to purchasing white-label formulations products, basically the switch for European generics companies from manufacturing to marketing, CEE markets still have low manufacturing …
